Deutsche Bank resumed coverage on payments and IT services stocks, with preference for high-quality fintech names like Visa ...

Investing.com -- Precision BioSciences (NASDAQ: DTIL) has received FDA Orphan Drug Designations for its nuclease treatments targeting Duchenne muscular dystrophy.

While a downgrade is unlikely given the positive outlook, Moody’s could affirm the Ba3 rating with a stable outlook if debt-to-EBITDA exceeds 4.5x, pre-tax income margin remains below 5.0%, large long ...